# AASLD 2018 Hepatitis B Guidance on Immunosuppressive Therapy

OpenHBV source page: https://openhbv.bangbo.dev/sources/aasld-2018-hepatitis-b-guidance-on-immunosuppressive-therapy?locale=en
Canonical Markdown: https://openhbv.bangbo.dev/sources/aasld-2018-hepatitis-b-guidance-on-immunosuppressive-therapy.md?locale=en
Original URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5975958/

## Metadata

- Organization: American Association for the Study of Liver Diseases
- Country or region: United States
- Language: en
- Source type: guideline
- Published: not listed
- Source updated: not listed
- Last checked by OpenHBV: 2026-06-26
- Credibility note: 专业肝病学会指南

## Summary

AASLD 2018 乙肝指导中关于免疫抑制或细胞毒性治疗相关 HBV 再激活预防、筛查、预防性抗病毒治疗和监测的建议。

## Related OpenHBV Articles

- Before chemotherapy, immunosuppression, or biologics: do not miss hepatitis B reactivation risk
  URL: https://openhbv.bangbo.dev/articles/before-chemotherapy-immunosuppression-or-biologics-do-not-miss-hepatitis-b-reactivation-risk?locale=en
  Markdown: https://openhbv.bangbo.dev/articles/before-chemotherapy-immunosuppression-or-biologics-do-not-miss-hepatitis-b-reactivation-risk.md?locale=en
  Translation key: article-8c0fbf61e461
  Language: en
  Topic: Treatment and Follow-up
  Published: 2026-06-26
  Review status: source_backed
  Last reviewed: 2026-06-26
  Summary: What HBV reactivation means, which treatments should trigger screening, and what to ask before cancer or immune-suppressing therapy starts.

## Use Notes

This page is a source record, not medical advice. Use the original source URL above to verify claims, publication details, updates, and scope. OpenHBV records the last checked date so readers and LLM retrieval systems can judge freshness.